--- title: "AstraZeneca (AZN) stock news, pipeline, cash and catalysts" url: "https://aibio.space/companies/astrazeneca/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AstraZeneca news for investors: AstraZeneca is a UK-based global drugmaker with large cancer, rare disease and cardiovascular, renal and respiratory…" --- Desk view · Opinion · Updated Oct 22, 2026 ## AstraZeneca leans on oncology and licensing to carry the post-Farxiga years AstraZeneca is growing on oncology and filling the pipeline through licenses, with two positive phase 3 readouts since July. Farxiga erosion, a failed heart trial for Wainua and $26.9 billion of net debt are the counterweights. ESMO on October 24 to 25 is the next test of how large the lung and gastric results are. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view Oncology growth and two positive phase 3 readouts support the business, offset by Farxiga erosion, the Wainua heart trial failure and $26.9 billion of net debt. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Strong in oncology.** Antibody-drug conjugates, biomarker-directed lung cancer combinations and a newly licensed EGFR exon 20 drug are all late stage. - **Odds**: **Good on lung and gastric programs.** Sone-ve and SAFFRON read out positively, while Wainua failed in ATTR-CM and three phase 3 trials missed primary endpoints, as reported with the first-half results. - **Balance sheet**: **Leveraged but cash generative.** Net debt was $26.9 billion at June 30, 2026, against $4.9 billion of cash. - **Main risk**: **Farxiga erosion.** BioPharmaceuticals revenue fell 1% in the first half as Farxiga lost U.S. exclusivity and faced China procurement. - **Watch next**: ESMO data on October 24 to 25, then nine-month results on October 30 and the Zegfrovy U.S. launch in the fourth quarter. ## Top news on AstraZeneca 1. 2026-08-05 Financings [Arcus ends last TIGIT phase 3 as Gilead gives up its three board seats](https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/) Arcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of 2028. ## Dates **October 23 to 27, 2026** ESMO: SAFFRON (Oct 25), CLARITY-Gastric01 (Oct 25), VOLGA (Oct 24) and other AstraZeneca phase 3 data [Source](https://www.biopharmawatch.com/news/AZN/astrazeneca-esmo-2026-pivotal-phase-iii-trials) **October 30, 2026** Nine-month and third-quarter 2026 results [Source](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026) **Fourth quarter 2026** Planned U.S. launch of Zegfrovy for EGFR exon 20 insertion NSCLC [Source](https://www.tabletscapsules.com/3639-News/627892-AstraZeneca-Completes-600M-Oral-Lung-Cancer-Deal-with-Dizal/) ## The money Cash and equivalents of $4,893 million, gross borrowings of $32,239 million and net debt of $26,912 million at June 30, 2026. [Source](https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/half-year-financial-report/9687613) Second-quarter 2026 total revenue of $15,384 million, up 6% (5% at constant exchange rates); first-half total revenue $30,672 million, up 9%. [Source](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026) ## Risks on the record - Farxiga's U.S. loss of exclusivity and volume-based procurement in China held back BioPharmaceuticals, whose revenue fell 1% in the first half. [Source](https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/half-year-financial-report/9687613) - Three phase 3 trials missed primary endpoints, as listed in the first-half report, including Wainua in ATTR-CM, and sone-ve missed one of two primary endpoints. [Source](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026) - Net debt was $26.9 billion at June 30, 2026, after two licensing deals with $800 million of combined upfront payments. [Source](https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/half-year-financial-report/9687613) ## Questions investors ask ### What is aibio.space's Investor Rank for AstraZeneca? 7 out of 10, our positive view. Oncology growth and two positive phase 3 readouts support the business, offset by Farxiga erosion, the Wainua heart trial failure and $26.9 billion of net debt. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What were AstraZeneca's first-half 2026 results? AstraZeneca reported first-half total revenue of $30.67 billion, up 9%, and core EPS of $5.21, up 12%. It kept 2026 guidance of mid-to-high single-digit revenue growth and low double-digit core EPS growth. [Source](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026) ### When does AstraZeneca report third-quarter 2026 results? AstraZeneca will report nine-month and third-quarter 2026 results on October 30, 2026. [Source](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026) ### What did AstraZeneca pay for Zegfrovy? AstraZeneca agreed to pay Dizal $600 million upfront and up to $900 million in milestones, plus tiered royalties, for global rights to Zegfrovy (sunvozertinib). A trade report said the license has been completed and a U.S. launch is planned for the fourth quarter of 2026. [Source](https://www.biospace.com/press-releases/dizal-announces-global-exclusive-license-agreement-with-astrazeneca-for-zegfrovy) ### Did Wainua work in the CARDIO-TTRansform heart trial? No. Ionis and AstraZeneca said the phase 3 trial of eplontersen in ATTR cardiomyopathy missed its primary endpoint. A monotherapy subgroup showed a nominal hazard ratio of 0.71, but patients on stabilizers saw no effect. [Source](https://www.businesswire.com/news/home/20260708332180/en/update-on-cardio-ttransform-phase-3-trial-of-eplontersen-in-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/) ### Which AstraZeneca data are due at ESMO 2026? ESMO runs October 23 to 27, 2026. AstraZeneca has five phase 3 trials listed, including VOLGA on October 24 and SAFFRON and CLARITY-Gastric01 on October 25. [Source](https://www.biopharmawatch.com/news/AZN/astrazeneca-esmo-2026-pivotal-phase-iii-trials) ### Is AstraZeneca a smaller reporting company? SEC records list AstraZeneca PLC's filer category as: Large accelerated filer. Source ### Where is AstraZeneca headquartered? SEC records list its business address as 1 FRANCIS CRICK AVENUE, CAMBRIDGE, CB2 0AA. Source ### When does AstraZeneca's fiscal year end? AstraZeneca PLC's fiscal year ends on December 31, per SEC records. Source ### What did AstraZeneca last file with the SEC? Its most recent filing in our record is a 6-K filed 2026-10-22. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/901832/000165495426009093/a9580z.htm) ### What was AstraZeneca called before? SEC records list these former names: ZENECA GROUP PLC. Source ### What industry is AstraZeneca in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ### Which other companies' news mentions AstraZeneca? AstraZeneca is named in 1 of our story about other companies, most recently: "Arcus ends last TIGIT phase 3 as Gilead gives up its three board seats" (Aug 5, 2026). [Source](https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/) ### How can I follow AstraZeneca (AZN) news? Press Follow on this page to add AstraZeneca to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming AstraZeneca so far, in Financings. Source ## Legal and investor matters Checked against AstraZeneca filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. Note 5 (Legal proceedings and contingent liabilities) of the H1/Q2 2026 results 6-K filed 2026-07-27 covers only significant developments since the 2025 Annual Report. It does not mention a securities class action or shareholder derivative suit. The only putative class action it lists is the Barone privacy matter, which it says no longer names AstraZeneca. [Source](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) 1. 2026-09-29 Other AstraZeneca to invest $2 billion in Summit Therapeutics equity On 2026-09-29 AstraZeneca announced an agreement to invest $2 billion in newly issued equity in Summit Therapeutics to accelerate development of ivonescimab, a PD-1/VEGF bispecific antibody, in combination with antibody drug conjugates. The companies also signed a clinical collaboration to evaluate AstraZeneca's sonesitatug vedotin with ivonescimab in gastrointestinal cancers. Each company retains development and commercial rights to its own medicines. [AstraZeneca Form 6-K filed 2026-09-29](https://www.sec.gov/Archives/edgar/data/901832/000165495426008615/a6704w.htm) 2. 2026-08-25 Financing AstraZeneca Finance LLC prices EUR 2.55 billion bond offering AstraZeneca announced on 2026-08-25 that its subsidiary AstraZeneca Finance LLC priced four tranches of Eurobonds totalling EUR 2.55 billion on 2026-08-24, guaranteed by AstraZeneca PLC. The tranches are EUR 700 million at 3.402% due 2030, EUR 600 million at 3.652% due 2032, EUR 500 million at 3.923% due 2035 and EUR 750 million at 4.169% due 2038. Closing was expected on 2026-09-01, and proceeds are for general corporate purposes. [AstraZeneca Form 6-K filed 2026-08-25](https://www.sec.gov/Archives/edgar/data/901832/000165495426007840/a9590r.htm) 3. 2026-07-27 Litigation Delaware court awards Syntimmune sellers further $181 million; AstraZeneca says it intends to appeal A Delaware state court case brought by the Syntimmune stockholders' representative alleges AstraZeneca breached the 2018 merger agreement by failing to use commercially reasonable efforts to achieve milestones. In September 2024 the court concluded the first $130 million milestone was achieved and that AstraZeneca had breached its efforts obligation. In June 2025 it awarded an additional $181 million in damages. In May 2026 it awarded AstraZeneca $11.1 million for the sellers' breach of a representation. AstraZeneca says it intends to appeal the adverse decisions. Delaware state court · Status: pending [AstraZeneca Form 6-K filed 2026-07-27 (Q2 2026 results)](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) 4. 2026-07-27 Litigation AstraZeneca settles University of Sheffield Lynparza dispute for $220 million AstraZeneca disclosed that in May 2026 it entered into a global settlement agreement with the University of Sheffield, resolving all disputes in litigation served in June 2024. Sheffield had alleged that AstraZeneca made misrepresentations to induce it to amend a patent licence agreement relating to Lynparza. AstraZeneca agreed to pay $220 million, and the company states that the matter has concluded. Status: settled [AstraZeneca Form 6-K filed 2026-07-27 (Q2 2026 results)](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) 5. 2026-07-27 Litigation Federal Circuit affirms invalidity of Wyeth patents in Tagrisso case AstraZeneca reports that in July 2026 the Federal Circuit affirmed a Delaware district court decision that the Wyeth patents asserted against Tagrisso were invalid. A jury had found infringement in May 2024 and awarded Wyeth $107.5 million in past damages, but the district court then granted judgment as a matter of law to AstraZeneca for lack of written description and enablement. U.S. Court of Appeals for the Federal Circuit; U.S. District Court for the District of Delaware [AstraZeneca Form 6-K filed 2026-07-27 (Q2 2026 results)](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) 6. 2026-07-27 Litigation Putative class action over patient genetic data drops AstraZeneca as defendant AstraZeneca's results filing says a putative class action was filed in March 2026 in Illinois federal court against AstraZeneca and others, alleging unlawful use of patient genetic information. In June 2026 plaintiffs filed a consolidated class action complaint that does not name AstraZeneca as a defendant. The company states that the matter has concluded for it. Illinois federal court [AstraZeneca Form 6-K filed 2026-07-27 (Q2 2026 results)](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) 7. 2026-07-27 Regulatory AstraZeneca settles Texas qui tam marketing lawsuit AstraZeneca reports that a qui tam suit unsealed in December 2022 in Harrison County, Texas, on behalf of the State of Texas, alleged unlawful marketing practices. The case moved to Travis County in November 2025, when the State of Texas intervened. In June 2026 the case settled for an amount AstraZeneca describes as immaterial, and the company states that the matter has concluded. Texas state court, Travis County · Status: settled [AstraZeneca Form 6-K filed 2026-07-27 (Q2 2026 results)](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) 8. 2026-07-27 Litigation AstraZeneca starts ICC arbitration against Sanofi over Beyfortus agreement AstraZeneca reports that in June 2026 it began an arbitration before the International Chamber of Commerce against Sanofi Pasteur Inc. over a collaboration agreement for the development and commercialisation of Beyfortus. The arbitration relates to alleged non-performance of certain obligations. Sanofi has filed counterclaims relating to AstraZeneca's obligations under the same agreement. International Chamber of Commerce (arbitration) · Status: pending [AstraZeneca Form 6-K filed 2026-07-27 (Q2 2026 results)](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Sonesitatug vedotin (sone-ve), CLDN18.2 ADC | 2L+ CLDN18.2-positive gastric/GEJ cancer | Phase 3 CLARITY-Gastric01 met OS goal, missed an overall-population PFS goal (Jul 27, 2026) [Source](https://www.astrazeneca.com/media-centre/press-releases/2026/sone-ve-improved-survival-in-gastric-cancers.html) | | Tagrisso plus Orpathys (savolitinib), with HUTCHMED | MET-driven EGFR-mutated NSCLC after Tagrisso | Phase 3 SAFFRON positive on PFS and OS (Aug 17, 2026); data due at ESMO Oct 25 [Source](https://www.astrazeneca.com/media-centre/press-releases/2026/tagrisso-orpathys-improved-pfs-os-egfrm-lung.html) | | Zegfrovy (sunvozertinib), licensed from Dizal | EGFR exon 20 insertion NSCLC | Approved in U.S. and China after platinum; first-line filings submitted; U.S. launch planned Q4 2026 [Source](https://www.biospace.com/press-releases/dizal-announces-global-exclusive-license-agreement-with-astrazeneca-for-zegfrovy) | | Baxfendy | Hypertension | FDA approved (reported in H1 2026 results); Japan submission [Source](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026) | | Tozorakimab | COPD | Submitted in EU and China [Source](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026) | | Wainua (eplontersen), with Ionis | ATTR cardiomyopathy | Phase 3 CARDIO-TTRansform missed primary endpoint (Jul 2026) [Source](https://www.businesswire.com/news/home/20260708332180/en/update-on-cardio-ttransform-phase-3-trial-of-eplontersen-in-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps AstraZeneca's releases match its filings, but lead with core figures and give few trial numbers AstraZeneca's half-year report is candid about the failed Wainua trial and the missed PFS goal for sone-ve, so we found no contradiction between releases and filings. The gaps are in framing: core EPS leads the key performance bullets while reported EPS grew 3% in the half year and fell 2% in the second quarter, both at constant rates, and two phase 3 releases call results clinically meaningful without giving hazard ratios. The legal note lists no securities class action. 1. Press release vs filing · weight medium Core EPS leads, reported EPS grew more slowly **The company said:** "Core Operating profit and Core EPS increased 11%" [source](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) **The record says:** The bullet is for the first half. The same table shows H1 Reported EPS of $3.60, up 4% as reported and 3% at constant exchange rates, against Core EPS of $5.21, up 12% (11% at constant rates). For the second quarter, Reported EPS was $1.61, up 2% as reported and down 2% at constant exchange rates, against Core EPS up 21% (18% at constant rates). It says the gap is "primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges." The footnote names legal settlements among the items excluded from Core measures. Separately, the legal note records a May 2026 settlement with the University of Sheffield for a payment by AstraZeneca of $220m. [source](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) **Our view:** The release gives both measures, so this is a matter of emphasis, not omission. Reported EPS grew less than Core EPS in both periods, and in the second quarter it fell at constant rates, which the bullets do not show. 2. Press release vs filing · weight medium Wainua miss is stated plainly, with a subgroup beside it **The company said:** "We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months." [source](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) **The record says:** The report says Wainua in ATTR-CM "did not meet the primary efficacy endpoint of the composite outcome of CV mortality and recurrent CV clinical events up to 140 weeks compared with placebo." It adds that a prespecified monotherapy subgroup result "was nominally significant" while "In patients who were on stabiliser therapy at baseline, no treatment effect was observed." AstraZeneca's separate 9 July 2026 update on the trial also reported the primary miss. [source](https://www.businesswire.com/news/home/20260708332180/en/update-on-cardio-ttransform-phase-3-trial-of-eplontersen-in-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/) **Our view:** AstraZeneca did not bury the failure, and the CEO calls it a disappointment. Because the subgroup was not the primary analysis, a nominal result there is a reason to look further, not evidence of benefit. 3. Science · weight high Sone-ve: the broad survival claim rests on a key secondary endpoint, and no numbers yet **The company said:** "Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers" [source](https://www.astrazeneca.com/media-centre/press-releases/2026/sone-ve-improved-survival-in-gastric-cancers.html) **The record says:** The release says the trial "met the dual primary endpoint of OS in 3rd and later-line treatment, and a key secondary endpoint of OS in the overall trial population" and that for PFS in the second-line-and-later population "results showed a trend toward improved PFS ... but did not reach statistical significance." It describes the trial as "randomised, open-label, sponsor-blinded". ClinicalTrials.gov lists 594 participants and two primary outcomes, PFS in all randomized participants and OS in 3L+ participants, with OS in all randomized participants as a secondary outcome. The H1 report's trial table labels CLARITY-Gastric01 as "Primary endpoint met", although its text discloses the PFS miss. [source](https://clinicaltrials.gov/study/NCT06346392) **Our view:** The headline claim covers the broader 2nd and later-line population, where OS was a key secondary endpoint, and the other primary endpoint, PFS, did not reach statistical significance. The release discloses both, but gives no survival gain or hazard ratio, so the size of the benefit is unknown until the data are presented at a medical meeting. 4. Science · weight medium SAFFRON: positive on PFS and OS, but open label against chemotherapy **The company said:** "First global Phase III trial to show significant progression-free and overall survival benefits in this setting" [source](https://www.astrazeneca.com/media-centre/press-releases/2026/tagrisso-orpathys-improved-pfs-os-egfrm-lung.html) **The record says:** The release describes SAFFRON as "a randomised, open-label, multi-centre, global Phase III trial" versus platinum chemotherapy in 338 patients, with "The primary endpoint is PFS and key secondary endpoints include OS and objective response rate." ClinicalTrials.gov lists one primary outcome, progression-free survival, and OS as a secondary outcome. [source](https://clinicaltrials.gov/study/NCT05261399) **Our view:** The trial is open label against chemotherapy, which means patients and investigators know the treatment, although ClinicalTrials.gov describes PFS as assessed by blinded independent central review. The release gives no hazard ratios, and OS was a key secondary endpoint, so the size of the survival result is not yet known. 5. Legal and disclosure record · weight low No securities litigation or enforcement disclosed in the latest filing **The record says:** The legal proceedings note in the H1 2026 report lists patent cases, commercial disputes and government matters. It says of the Texas qui tam case "In June 2026, the case settled for an immaterial amount" and of the University of Sheffield dispute "in exchange for payment by AstraZeneca of $220m." A putative class action over patient genetic information (Barone Privacy Litigation, Illinois federal court, filed March 2026) was followed by a consolidated complaint in June 2026 "not naming AstraZeneca as a defendant." The government section also lists a False Claims Act qui tam brought by a relator on behalf of the United States and several states in the US District Court for the Central District of California (340B Qui Tam), where the Ninth Circuit reversed a dismissal in March 2026 and the note describes it as a contingent liability. The note lists no securities class action, and it does not say the United States has intervened in that case. [source](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) **Our view:** The disclosed matters are mostly contract, patent and pricing disputes, several now concluded. The 340B qui tam is described as a contingent liability, and the Texas qui tam, Sheffield and Barone matters are marked concluded in the note. Documents we compared - [AstraZeneca H1 and Q2 2026 results, Form 6-K](https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm) 2026-07-27 - [AstraZeneca CLARITY-Gastric01 sonesitatug vedotin release](https://www.astrazeneca.com/media-centre/press-releases/2026/sone-ve-improved-survival-in-gastric-cancers.html) 2026-07-27 - [AstraZeneca SAFFRON Tagrisso plus Orpathys release](https://www.astrazeneca.com/media-centre/press-releases/2026/tagrisso-orpathys-improved-pfs-os-egfrm-lung.html) 2026-08-17 - [Ionis and AstraZeneca CARDIO-TTRansform update](https://www.businesswire.com/news/home/20260708332180/en/update-on-cardio-ttransform-phase-3-trial-of-eplontersen-in-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/) 2026-07-08 - [ClinicalTrials.gov NCT06346392 (CLARITY-Gastric01)](https://clinicaltrials.gov/study/NCT06346392) 2026-10-15 - [ClinicalTrials.gov NCT05261399 (SAFFRON)](https://clinicaltrials.gov/study/NCT05261399) 2026-08-06 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open LSE:AZN on TradingView](https://www.tradingview.com/symbols/LSE-AZN/). ## SEC filings and registration - **SEC name**: Astrazeneca Plc - **CIK**: 901832 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AZN (NYSE) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 1 FRANCIS CRICK AVENUE, CAMBRIDGE, CB2 0AA - **Phone**: 011 44 20 7304 5000 - **Former names**: ZENECA GROUP PLC ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009093/a9580z.htm) filed 2026-10-22 - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008783/a6290x.htm) filed 2026-10-05 - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008760/a3874x.htm) filed 2026-10-02 - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008741/a2108x.htm) filed 2026-10-01 - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008739/a2082x.htm) filed 2026-10-01 - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008615/a6704w.htm) filed 2026-09-29 - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008520/a8652v.htm) filed 2026-09-23 - [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008478/a4455v.htm) filed 2026-09-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/astrazeneca/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "AstraZeneca (AZN) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/astrazeneca/